Sezen Irmak Gözükara

Dr. Sezen Irmak Gözükara

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2023 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
SUSena Boncuk Ulaş
Sena Boncuk Ulaş
YAYeşim Güzey Aras
Yeşim Güzey Aras
SGSezen Irmak Gözükara
Sezen Irmak Gözükara
TATürkan Acar
Türkan Acar
Bilgehan Atılgan AcarBilgehan Atılgan Acar
Bilgehan Atılgan Acar

1 December 2021 in Revue Française d'Allergologie
Verified
Journal Article
Closed access
KTK. Terzioglu
K. Terzioglu
SGSezen Irmak Gözükara
Sezen Irmak Gözükara
AKA. Kant
A. Kant

16 January 2025 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
OKOsman Köse
Osman Köse
KGKORAY GÖK
KORAY GÖK
EKElif Kose
Elif Kose
SGSezen Irmak Gözükara
Sezen Irmak Gözükara
ATAbdullah Tuten
Abdullah Tuten
MBMehmet Sühha Bostancı
Mehmet Sühha Bostancı
Background: Insulin-regulated aminopeptidase (IRAP) is involved in insulin sensitivity and glucose metabolism and is important in the pathophysiology of type 2 diabetes. Serum IRAP levels are strongly associated with type 2 diabetes and insulin resistance. The aim of this study was to evaluate the IRAP level as a potential biomarker for the early diagnosis and management of insulin resistance in women with gestational diabetes mellitus (GDM). Methods: This cohort study included 40 women with GDM and 40 women with healthy pregnancies. Maternal serum IRAP levels were measured with enzyme-linked immunosorbent assay (ELISA) and compared between the two groups. Results: The mean serum IRAP level was significantly lower in the GDM group (0.73 ± 0.12 ng/mL) compared to the controls (0.92 ± 0.10 ng/mL) (p = 0.001). Pairwise comparisons indicated, that diet modified and insulin treated GDM subgroups had significantly lower serum IRAP levels than the control group (p < 0.017 and p < 0.017, respectively). Serum IRAP levels showed significant negative correlations with fasting glucose, insulin, homeostatic model assessment of insulin resistance (HOMA-IR) levels and hemoglobin A1c (HbA1c) (r = –0.541, p = 0.001; r = –0.447, p = 0.001; r = –0.584, p = 0.001; r = –0.361, p = 0.001). The optimum serum IRAP cut-off value was calculated to be 0.857 ng/mL, with a sensitivity of 85% and a specificity of 80% for the prediction of GDM (p = 0.001). Conclusions: The serum IRAP level in pregnant women diagnosed with GDM was significantly lower than in healthy pregnant women. Moreover, the serum IRAP level was negatively correlated with the levels of insulin, HbA1c, and HOMA-IR. These findings suggest that low serum IRAP level could be a novel biomarker for the prediction of GDM. Clinical Trial registration: The study has been registered on https://classic.clinicaltrials.gov/ (registration number: NCT06716320).

1 January 2026 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
OKOsman Köse
Osman Köse
KGKORAY GÖK
KORAY GÖK
EKElif Kose
Elif Kose
SGSezen Irmak Gözükara
Sezen Irmak Gözükara
ATAbdullah Tuten
Abdullah Tuten
MBMehmet Sühha Bostancı
Mehmet Sühha Bostancı
Objective: To measure serum insulin-regulated aminopeptidase levels in women diagnosed with polycystic ovary syndrome and to investigate their potential contribution of these levels to the development of insulin resistance, which plays a central role in the pathophysiology of polycystic ovary syndrome. Methods: The study group, recruited between May and December 2021, consisted of 40 patients diagnosed with polycystic ovary syndrome and 40 age-matched healthy controls. Serum insulin-regulated aminopeptidase levels were compared between the groups using the ELISA method. Results: [...] ABSTRACT Objective: To measure serum insulin-regulated aminopeptidase levels in women diagnosed with polycystic ovary syndrome and to investigate their potential contribution of these levels to the development of insulin resistance, which plays a central role in the pathophysiology of polycystic ovary syndrome. Methods: The study group, recruited between May and December 2021, consisted of 40 patients diagnosed with polycystic ovary syndrome and 40 age-matched healthy controls. Serum insulin-regulated aminopeptidase levels were compared between the groups using the ELISA method. Results:

20 October 2022 in Konuralp Tip Dergisi
Verified
Journal Article
Closed access
FŞfatih şahin
fatih şahin
MOMustafa Orhan
Mustafa Orhan
ATAyça Taş Tuna
Ayça Taş Tuna
OPOnur Palabiyik
Onur Palabiyik
NBNevcihan SAHUTOGLU BAL
Nevcihan SAHUTOGLU BAL
HÇHüseyin Çakiroğlu
Hüseyin Çakiroğlu
Objective: N-Methyl D-Aspartate (NMDA) receptor blockers have been shown to have protective effects against ischemia/reperfusion (I/R) injury in various tissues. The aim of this study was to investigate the effects of 90 ve 135 mg/kg doses of amantadine on lung in hepatic I/R injury. Method: The rats were randomly divided into six groups: Group Sham, Group I/R, Group Amantadine-90, Group Amantadine-135, Group I/R-90 and Group I/R-135. In I/R, an atraumatic vascular clamp was applied to the structures in the left portal triad for 45 minutes and reperfusion period was 2 hours after ischemia. Malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT) enzyme levels were performed the lung tissue and tissues were examined histopathologically. Result: A significant difference was found between the groups in terms of MDA, SOD, CAT levels (respectively; p < 0.001, p=0.008, p < 0.001). A significant difference was found between the groups in terms of lung tissue neutrophil/lymphocyte infiltration scores and alveolar wall thickening scores (respectively p=0.009, p=0.002). Conclusion: The biochemical and histopathological results of the present study suggested that amantadine, like other NMDA antagonist agents, may have a protective effect on lung tissues against the damage caused by hepatic I/R injury. Although we observed significant improvements after the administration of both doses studied, there was no significant difference between these two doses in terms of their success in protecting against distant organ lung injury. Amantadine appears promising as a therapeutic agent in treatment.

8 August 2025 in Bratislava Medical Journal
Verified
Journal Article
Closed access
PDF file
NCNimet uçaroğlu can
Nimet uçaroğlu can
SUSena Boncuk Ulaş
Sena Boncuk Ulaş
YAYeşim Güzey Aras
Yeşim Güzey Aras
SGSezen Irmak Gözükara
Sezen Irmak Gözükara
TATürkan Acar
Türkan Acar
Bilgehan Atılgan AcarBilgehan Atılgan Acar
Bilgehan Atılgan Acar